← Leaderboards
Michael James Burke
University Of Minnesota
$341,131
Attributed
$682,261
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $360.3K · FY2011–12$500K$375K$250K$125K$0
'11
'12
Funding mix
By agency
NIH$682,261 · 1
By mechanism
R21$682,261 · 1
Top collaborators
- Patrick A Brown3 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Brenda J. Weigel$37,619,294
- Jenny N. Poynter$12,330,101
- Erin Marcotte$4,498,384
- Steven E Patterson$9,957,982
- Timothy C. Hallstrom$2,085,765
Others in their field
Top investigators on “Aftercare”
- Sharon A Nachman · Johns Hopkins University$78,205,219
- Mary M Horowitz · Medical College Of Wisconsin$74,193,785
- Dan H. Barouch · Fred Hutchinson Cancer Center$60,753,467
- Georgia D Tomaras · Fred Hutchinson Cancer Center$58,263,037
- Lawrence Corey · Fred Hutchinson Cancer Center$58,263,037
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$58,263,037
Research focus
AftercareAdultBaseBiologicalBiomarkerApoptosisCancer CellCessation Of LifeChemotherapyChildChildhoodChildhood LeukemiaChildren&AposBone MarrowClinical TrialsCommunitiesComplement 3d ReceptorsCorrelative StudyCytotoxicityDecitabineDiagnosisDisease RemissionDna MethylationDoxorubicin
Grant awards (3)
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$261,845
R21 · FY2012 · CA · contact PI
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$60,086
R21 · FY2012 · CA · contact PI
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$360,330
R21 · FY2011 · CA · contact PI